An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.

作者: Karen Antman , John Crowley , Stanley P Balcerzak , Saul E Rivkin , Geoffrey R Weiss

DOI: 10.1200/JCO.1993.11.7.1276

关键词: IfosfamideBone SarcomaMesnaSurgeryInternal medicineChemotherapyRhabdomyosarcomaOncologyDoxorubicinDacarbazineSarcomaMedicine

摘要: PURPOSE AND METHODSDoxorubicin alone or with dacarbazine (DTIC; AD) is considered the best available therapy for metastatic adult sarcomas. Ifosfamide active in sarcomas that have failed to respond a doxorubicin-based regimen. This study was designed determine if ifosfamide added doxorubicin and DTIC (ADI) significantly effects toxicity, response rate, survival. Patients measurable unresectable sarcoma were randomized receive AD ADI. chondrosarcomas, fibrosarcomas, other of bone eligible, although those osteosarcoma, rhabdomyosarcoma, Ewing's sarcoma, Kaposi's mesothelioma excluded, as patients prior chemotherapy doxorubicin.RESULTSBetween 1987 1989, 340 eligible randomized. Significantly more myelosuppression, higher rate (17% v 32%; P < .002) longer time progression (4 6 months; .02) observed who received ifosfamide. An...

参考文章(31)
H. M. Pinedo, V. H. C. Bramwell, H. T. Mouridsen, R. Somers, C. P. J. Vendrik, A. Santoro, J. Buesa, Th. Wagener, A. T. van Oosterom, J. A. M. van Unnik, R. Sylvester, M. de Pauw, D. Thomas, O. Bonadonna, Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules: A study of the EORTC soft tissue and bone sarcoma group Cancer. ,vol. 53, pp. 1825- 1832 ,(1984) , 10.1002/1097-0142(19840501)53:9<1825::AID-CNCR2820530904>3.0.CO;2-Z
G. A. Omura, F. J. Major, J. A. Blessing, T. V. Sedlacek, J. T. Thigpen, W. T. Creasman, R. J. Zaino, A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas Cancer. ,vol. 52, pp. 626- 632 ,(1983) , 10.1002/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO;2-E
Robert M. O'Bryan, James K. Luce, Robert W. Talley, Jeffrey A. Gottlieb, Laurence H. Baker, Gianni Bonadonna, Phase II evaluation of adriamycin in human neoplasia Cancer. ,vol. 32, pp. 1- 8 ,(1973) , 10.1002/1097-0142(197307)32:1<1::AID-CNCR2820320101>3.0.CO;2-X
Vivien H.C. Bramwell, H.T. Mouridsen, A. Santoro, G. Blackledge, R. Somers, J. Verwey, P. Dombernowsky, M. Onsrud, D. Thomas, R. Sylvester, A. Van Oosterom, Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas European Journal of Cancer and Clinical Oncology. ,vol. 23, pp. 311- 321 ,(1987) , 10.1016/0277-5379(87)90075-7
E.T. Creagan, R.G. Hahn, D.L. Ahmann, H.F. Bisel, A clinical trial adriamycin (NSC 123127) in advanced sarcomas. Oncology. ,vol. 34, pp. 90- 91 ,(1977) , 10.1159/000225192
J de Kraker, Pa Voute, Ifosfamide and vincristine in paediatric tumours. A phase II study European Paediatric Haematology and Oncology. ,vol. 1, pp. 47- 50 ,(1984) , 10.3109/08880018409141708
Louis A. Lanza, Joe B. Putnam, Robert S. Benjamin, Jack A. Roth, Response to chemotherapy does not predict survival after resection of sarcomatous pulmonary metastases. The Annals of Thoracic Surgery. ,vol. 51, pp. 219- 224 ,(1991) , 10.1016/0003-4975(91)90789-S
R. M. O'Bryan, L. H. Baker, J. E. Gottlieb, S. E. Rivkin, S. P. Balcerzak, G. N. Grumet, S. E. Salmon, T. E. Moon, B. Hoogstraten, Dose response evaluation of adriamycin in human neoplasia Cancer. ,vol. 39, pp. 1940- 1948 ,(1977) , 10.1002/1097-0142(197705)39:5<1940::AID-CNCR2820390505>3.0.CO;2-0
D. R. Cox, E. J. Snell, analysis of binary data ,(1970)